Mark T Dransfield MD

Pulmonology•Birmingham, AL

Critical Care Medicine

Professor, Medicine, University of Alabama School of Medicine

Join to View Full Profile

2000 6th Ave SBirmingham, AL 35233
Phone+1 205-934-9999
Fax+1 205-975-5666

Summary

Medical Director, UAB Lung Health Center

Education & Training

University of Alabama Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2003
University of Alabama Medical CenterResidency, Internal Medicine, 1997 - 2000
University of North Carolina at Chapel Hill School of MedicineClass of 1997

Certifications & Licensure

AL State Medical License 1998 - 2025
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study Start of enrollment: 2007 Feb 01
Completed
Phase 2
Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study Start of enrollment: 2008 Feb 01
Completed
Phase 2
Long-term Oxygen Treatment Trial Start of enrollment: 2009 Jan 01
Completed
Phase 3
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema Start of enrollment: 2009 Mar 01
Terminated
Phase 2
Simvastatin Therapy for Moderate and Severe COPD Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA) Start of enrollment: 2010 Nov 01
Completed
Phase 2
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2012 Apr 01
Completed
Phase 4
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study Start of enrollment: 2012 Oct 01
Terminated
Not Applicable
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Start of enrollment: 2013 Jul 01
Completed
Not Applicable
Study of COPD Subgroups and Biomarkers
ACTIVE_NOT_RECRUITING
TOPIC Trial for COPD Start of enrollment: 2015 May 01
Completed
Early Phase 1
Evaluation of COPD Co-Pilot Start of enrollment: 2016 Oct 01
Unknown status
The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor Start of enrollment: 2017 Mar 16
COMPLETED
PHASE2
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency Start of enrollment: 2019 Apr 08
COMPLETED
PHASE2
The Multicenter Topic Trial Start of enrollment: 2021 Dec 01
Withdrawn
Phase 2
COVID-19 Study of Safety and Tolerability of Alvelestat Start of enrollment: 2021 Jan 25
Completed
Phase 1, Phase 2
An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI Start of enrollment: 2020 Jun 28
COMPLETED
SPIROMICS Study of Early COPD Progression (SOURCE) Start of enrollment: 2021 Sep 08
RECRUITING
Join now to see all

Publications & Presentations

PubMed

Phenotypes and Trajectories of Tobacco-exposed Persons with Preserved Spirometry: Insights from Lung Volumes.
Mehrdad Arjomandi, Siyang Zeng, Igor Barjaktarevic, Eugene R Bleecker, Russell P Bowler
Annals of the American Thoracic Society. 2025-04-01
Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry.
Spyridon Fortis, Matthew Strand, Surya P Bhatt, Patrick Ten Eyck, Linder Wendt
American Journal of Respiratory and Critical Care Medicine. 2025-02-13
1 citations
ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.
R Chad Wade, Fernando J Martinez, Gerard J Criner, Lee Tombs, David A Lipson
The European Respiratory Journal. 2025-02-01

Journal Articles

Association of Dysanapsis with Chronic Obstructive Pulmonary Disease Among Older Adults
Alain Bertoni, Gerard Criner, Mark T Dransfield, Meilan K Han, Nadia N Hansel, Erin D Michos, Elizabeth C Oelsner, Karol E Watson, JAMA